{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1201900.0","upperLimit":"32984400.0","value":"1973400.0"},{"groupId":"OG001","lowerLimit":"780.0","upperLimit":"25000000.0","value":"3681400.0"},{"groupId":"OG002","lowerLimit":"780.0","upperLimit":"25000000.0","value":"1979360.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Peak was defined as the maximum post-baseline level of the cytokine.","dispersionType":"Full Range","groups":[{"description":"Participants with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL) received conditioning chemotherapy (fludarabine 30 mg/m\\^2 intravenously \\[IV\\] over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel chimeric antigen receptor (CAR) transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of body weight (BW) on Day 0.","id":"OG000","title":"Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy"},{"description":"Participants with refractory DLBCL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0.","id":"OG001","title":"Phase 2 (Pivotal Study): Cohort 1"},{"description":"Participants with refractory PMBCL or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0.","id":"OG002","title":"Phase 2 (Pivotal Study): Cohort 2"}],"paramType":"MEDIAN","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 3","title":"Pharmacodynamics: Peak Level of Cytokine (Ferritin) in Serum (Phase 1 and Phase 2 Cohorts 1 and 2)","type":"SECONDARY","unitOfMeasure":"pg/mL"}